Does cannabidiol protect against the negative effects of THC?

British Journal of Psychiatry

Volumn 197, Issue 4, 2010, Pages 259-260

  Henquet, Cécile ^a   Kuepper, Rebecca ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; DRONABINOL;

COGNITION; DRUG EFFECT; GENETIC ASSOCIATION; HUMAN; MEMORY; MENTAL HEALTH; NEUROPROTECTION; REVIEW; RISK FACTOR;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CANNABIDIOL; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS; TETRAHYDROCANNABINOL;

EID: 77957672849     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.110.081380     Document Type: Review

References (10)

1. Morgan CJA, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 2010; 197: 285-90.
2. Potter DJ, Clark P, Brown MB. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 2008; 53: 90-4.
3. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009; 195: 488-91.
4. Morgan CJA, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008; 192: 306-7.
5. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2009; 35: 764-74.
6. Leweke M, Schneider U, Radwan M, Schmidt E, Emrich HM. Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol Biochem Behav 2000; 66: 175-81. (Pubitemid 30317532)
7. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9- tetrahydrocannabivarin. Br J Pharmacol 2008; 153: 199-215.
8. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006; 39: 421-9.
9. Leweke FM, Koethe D, Pahlisch F, Schreiber D, Gerth CW, Nolden BM, et al. Antipsychotic effects of cannabidiol. European Psychiatry 2009; 24 (suppl 1): S207.
10. Henquet C, van Os J, Kuepper R, Delespaul P, Smits M, á Campo J, et al. Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry 2010; 196: 447-53.